NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.05 +0.02 (+1.94 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$1.05
Today's Range$1.02 - $1.07
52-Week Range$0.72 - $1.80
Volume535,082 shs
Average Volume396,293 shs
Market Capitalization$28.70 million
P/E Ratio-1.30
Dividend YieldN/A
Beta1.83
Interpace Diagnostics Group logoInterpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419

Debt

Debt-to-Equity RatioN/A
Current Ratio2.59
Quick Ratio2.59

Price-To-Earnings

Trailing P/E Ratio-1.30
Forward P/E Ratio-2.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.90 million
Price / Sales1.84
Cash FlowN/A
Price / CashN/A
Book Value$1.48 per share
Price / Book0.71

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-12,210,000.00
Net Margins-103.40%
Return on Equity-46.58%
Return on Assets-33.66%

Miscellaneous

Employees75
Outstanding Shares27,870,000
Market Cap$28.70

Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) posted its quarterly earnings data on Tuesday, May, 15th. The business services provider reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The business services provider earned $4.81 million during the quarter, compared to analysts' expectations of $4.30 million. Interpace Diagnostics Group had a negative net margin of 103.40% and a negative return on equity of 46.58%. View Interpace Diagnostics Group's Earnings History.

What price target have analysts set for IDXG?

4 brokers have issued 12-month price objectives for Interpace Diagnostics Group's stock. Their forecasts range from $2.25 to $4.50. On average, they expect Interpace Diagnostics Group's stock price to reach $3.1875 in the next year. This suggests a possible upside of 203.6% from the stock's current price. View Analyst Ratings for Interpace Diagnostics Group.

What is the consensus analysts' recommendation for Interpace Diagnostics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Interpace Diagnostics Group stock?

Here are some recent quotes from research analysts about Interpace Diagnostics Group stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks. Our price target is derived from a market value of the firm at $106M, which includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate. Risks include: (1) failure of the company’s LDTs to secure reimbursement; (2) failure of the company’s LDTs to achieve commercial success due to lower-than-expected market size and/or penetration rates, and/or greater competition; and (3) potential dilution risk." (7/20/2018)
  • 2. Maxim Group analysts commented, "Interpace announced that they will be expanding the applications for PancraGEN beyond pancreatic cysts to include both biliary strictures and solid pancreatic lesions. The company bases this expansion on both new Network (NCCN) guidelines as well as the results of several independent research publications, both of which are discussed below." (7/19/2018)
  • 3. According to Zacks Investment Research, "Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey. " (7/18/2018)

Who are some of Interpace Diagnostics Group's key competitors?

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:
  • Mr. Jack E. Stover, CEO, Pres and Director (Age 65)
  • Mr. James E. Early, CFO, Sec. & Treasurer (Age 64)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 51)
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)
  • Mr. Patrick Kane, VP & Corp. Controller

Has Interpace Diagnostics Group been receiving favorable news coverage?

News stories about IDXG stock have trended positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 0.36 on Accern's scale. They also assigned press coverage about the business services provider an impact score of 45.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $1.05.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $28.70 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Group employs 75 workers across the globe.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]


MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.